Table 3.

Incidence of AEs and ADRs

	Placebo (n = 20)		Dotinurad
			1 mg (n = 20)		2 mg (n = 19)		4 mg (n = 21)		Total (n = 60)
	AEs	ADRs	AEs	ADRs	AEs	ADRs	AEs	ADRs	AEs	ADRs
Number of events	16	4	7	3	21	8	18	3	46	14
Number of patients	7	3	6	3	12	5	11	2	29	10
Incidence (%)	35.0	15.0	30.0	15.0	63.2	26.3	52.4	9.5	48.3	16.7
χ2 test	P vs. 1 mg	P vs. 2 mg	P vs. 4 mg	1 mg vs. 2 mg	1 mg vs. 4 mg	2 mg vs. 4 mg	P vs. total		Cochran–Armitage test
P value (AEs)	0.736	0.079	0.262	0.038*	0.146	0.491	0.299		0.089
P value (ADRs)	1.000	0.382	0.592	0.382	0.592	0.163	0.861		0.859

Incidence (%) = Number of patients/Number of analyzed patients × 100

Cochran–Armitage test was used in the 1, 2, and 4 mg, and placebo groups

P placebo, Total total of dotinurad

*P < 0.05